Business Wire · Jul 2026
Deep Genomics named Thong Q. Le chair of its board, with Chip Baird moving to chair the audit committee; the company said Le will help guide its next phase of growth and clinical pipeline progress.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Deep Genomics Inc. is a private Toronto-founded AI-first TechBio/biotechnology company developing genetic medicines. It combines computational biology, machine learning, RNA biology, automation, and experimental data to discover and develop therapeutics for genetically defined diseases. The company has been transitioning from a platform company toward a forward-integrated biopharmaceutical company.
Primary product
The Biological Foundation Model (BioFM) Platform, including BigRNA and related models such as REPRESS, evolved from the AI Workbench. It combines AI model development, fit-for-purpose biological datasets, lab-in-the-loop workflows, screening technologies, and software systems to decode RNA biology, identify therapeutic targets, and design RNA/oligonucleotide medicines.
Founded
2014
Headquarters
480 University Avenue, Suite 1300, Toronto, Ontario M5G 1V2, Canada
Team size
80–90 (LinkedIn-derived estimate; another database reports 101–250)
Work style
Hybrid
Industry
Biotechnology Research
Sub-industry
AI-enabled drug discovery, RNA therapeutics, computational biology, genetic medicines
Offices
480 University Avenue, Suite 1300, Toronto, Ontario M5G 1V2, Canada
1 Canal Park, Suite 300, Cambridge, Massachusetts 02141, USA
Business model
Internal discovery and development of proprietary genetic-medicine programs
Biopharmaceutical partnerships and co-development
Platform-enabled target and therapeutic discovery
Potential licensing or partnering of internally discovered programs
Funding
Stage
Series C / late-stage private biotech
Total raised
$236.7M
Latest round
Series C · Jul 2021
Latest amount
$180M
Jul 2021 · SoftBank Vision Fund 2
Jan 2020 · Future Ventures
Sep 2017 · Khosla Ventures
Series A / follow-on financing
Sep 2017 · Khosla Ventures
Nov 2015 · True Ventures
Nov 2015 · True Ventures
Corporate Round
Jan 2014
People & investors
Leadership
Chief Executive Officer
Founder, Chief Innovation Officer, and Board Member
Radu Dobrin
Chief Technology Officer
Chief Scientific Officer
Joel Shor
VP and Head of Machine Learning
Clive Bertram
Chief Business Officer
Chief Operating Officer
Harry Patterson
VP Finance
Laurence MacPhie
Vice President
Shawdee Eshghi
VP, Platform Biology
Thong Q. Le
Chair of the Board of Directors
Founders
Andrew Delong
Co-founder (database-reported)
Hannes Bretschneider
Co-founder and Chief Software Architect (database-reported)
Hui Yuan Xiong
Co-founder (database-reported; later reported as former co-founder)
Work & culture
Public materials describe a multidisciplinary, collaborative environment spanning machine learning, software engineering, computational biology, molecular biology, chemistry, and drug development. The company emphasizes a shared understanding of AI, software engineering, and RNA biology, with teams in Toronto and Cambridge. Public employer evidence is limited and third-party ratings are mixed.
Work style
Hybrid
Visa sponsorship
Limited
Compensation
A current Toronto Senior Research Scientist, Machine Learning listing gave a base salary range of C$175,000–C$200,000, plus competitive compensation and meaningful equity; U.S. compensation may differ. Historical U.S. immigration records show one green-card certification and no recent H-1B LCAs, so sponsorship should be treated as role- and location-dependent.
Benefits
Health, vision, and dental coverage for employees and families
Employee and family assistance program
Meaningful stock ownership
Flexible hours
Extended long weekends
Holiday shutdown
Unlimited personal days
Maternity and parental-leave top-up coverage
New-parent paid time off
Learning and development budget
Lunch-and-learn programs
Product & market
Pricing
No public list pricing or self-serve pricing found. The apparent model is enterprise biopharma collaboration, co-development, milestone economics, and potential licensing rather than a conventional software subscription.
Differentiators
- —Integrated AI, biological data, software, automation, and experimental validation rather than a standalone prediction tool
- —Focus on RNA biology and genetically precise medicines
- —BigRNA/BioFM foundation-model approach for decoding RNA biology and designing therapeutics
- —Lab-in-the-loop model development and fit-for-purpose datasets
- —Forward integration into proprietary therapeutic programs
- —Large-scale prediction across genetic variants, RNA mechanisms, and candidate compounds
Technology
BigRNA
REPRESS
Biological Foundation Models
machine learning and deep learning
RNA biology and RNA sequencing
bioinformatics
lab-in-the-loop workflows
high-throughput screening and automation
Python
PyTorch
TensorFlow
MLflow
CUDA
Kubernetes
Docker
Nextflow
Google Cloud Platform
Terraform
React
TypeScript
Customers
BioMarin Pharmaceutical Inc. (publicly disclosed preclinical collaboration; financial terms undisclosed)
Competitors
Recursion Pharmaceuticals
Insitro
Atomwise
Cyclica
Phenomic AI
Valence Discovery
Exscientia
Encoded Therapeutics
HelixNano
Scale & contact
Estimated revenue
$1M–$10M; one third-party estimate is approximately $5M annually, not company-reported
Estimated monthly visits
9.2K
Traffic estimate as of Jun 2026
Latest news
Deep Genomics · Oct 2025
Deep Genomics added Thong Q. Le and Paul Sekhri to the board, emphasizing strategic life-sciences and deal-making experience as the company advances AI-powered genetic medicines.
Deep Genomics · Jun 2025
The company appointed Vic Myer as chair and Richard Scheller to its Scientific Advisory Board to support AI-driven genomic R&D and drug discovery.
Deep Genomics · May 2025
Deep Genomics announced REPRESS, a new model predicting miRNA binding and mRNA degradation from sequence, and released it for non-commercial use via GitHub.
Deep Genomics · Jun 2024
Deep Genomics announced a Cambridge, MA office/lab opening, Toronto expansion, and executive hires including Radu Dobrin (CTO), Greg Hoffman (CSO), Joel Shor (VP/Head of ML), and Clive Bertram (CBO).
Jobs and careers at Deep Genomics
3 jobs at Deep Genomics
Senior Research Associate, in vivo Pharmacology
On-site
Cambridge, MA
1w ago
On-site
Full-time
Senior Research Scientist, Machine Learning (BioFM)
Hybrid
Toronto, Ontario
3mo ago
Hybrid
Full-time
Senior Scientist, Analytical Chemistry
Hybrid
Cambridge, MA
4mo ago
Hybrid
Full-time